FDA Clearance Tracker · P190014
myChoice HRD CDx
Last checked: Nov 20, 2026Latest source record: Oct 23, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Oct 23, 2019
Approved
Time to decision
173 days
Received May 3, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P190014
- Device name
- myChoice HRD CDx
- Applicant
- Myriad Genetic Laboratories, Inc.
- Applicant location
- Salt Lake City, UT
- Received
- May 3, 2019
- Decided
- Oct 23, 2019
- Decision
- Approved
- Supplements
- 11 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of Myriad myChoice® CDx. Myriad myChoice® CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status for treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling.Table1---Tumor Type: Ovarian Cancer, Biomarker: Myriad HRD (defined as deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score), Therapy: Zejula® (niraparib)
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PJG. The earliest in FDA's data is P140020, decided Dec 19, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Myriad Genetic Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.